Ruxolitinib to prevent GVHD in stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your blood cancer is in remission (blasts under 5%, no spread) or you have lymphoma that has responded to treatment.
- You have a matched or half-matched stem cell donor (related or unrelated).
- You are generally in good health and able to do daily activities (Karnofsky score 70% or more).
- If you are a woman who could become pregnant, you must use two reliable forms of birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether starting ruxolitinib early, guided by a blood marker, can prevent acute graft-versus-host disease (aGVHD) after a stem cell transplant. It's for people who have already had a transplant and are at risk for this complication.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
This trial tests whether adding stem cells (remestemcel-L) to ruxolitinib—a medication that helps control the immune system—can help treat severe graft-versus-host disease (GVHD) that hasn't responded to steroids. GVHD is a complication after bone marrow or stem cell transplant where the new immune cells attack your body.
Hear when a new Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.